Business Context and Reporting Period
Gossamer Bio, Inc. (GOSS) filed a Form 8-K on June 16, 2025, to disclose a significant clinical milestone. The company is a biopharmaceutical firm focused on pulmonary arterial hypertension (PAH).
Key Financial Metrics
This filing is a current report regarding a clinical trial event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Milestones
The primary event reported is the completion of enrollment for the Phase 3 PROSERA Study evaluating seralutinib in Functional Class II and III PAH patients. Key characteristics of the enrolled population include:
- Total Participants: 390 patients enrolled.
- Functional Class: 74% (289 patients) are in Functional Class III.
- Geographic Distribution: 81% (315 patients) from the Rest of World; 19% (75 patients) from North America.
- Baseline Metrics: Mean 6MWD of 374 meters and Mean NT-proBNP of 987 ng/L.
The study utilizes enrichment criteria, including the REVEAL Lite 2 Risk Score, to identify patients likely to show a greater magnitude of effect on 6MWD at week 24.
Guidance, Outlook, and Risks
Outlook: The Company expects to announce topline results from the Phase 3 PROSERA Study in February 2026.
Contingencies: The baseline characteristics provided are preliminary and subject to change.
Risks: As with all clinical trials, there is inherent risk that the study may not meet its primary endpoints, which could impact the regulatory approval of seralutinib.
Investor Verification Checklist
- Verify the final topline results of the PROSERA Study when announced in February 2026.
- Monitor the company's cash runway and liquidity status in subsequent quarterly filings (10-Q/10-K), as this 8-K contains no financial data.
- Review the full text of the press release (Exhibit 99.1) for any additional details on the study design or safety profile.
- Confirm the regulatory timeline for a potential New Drug Application (NDA) submission following the topline results.